Newsgather

evolution

مستقر358 خبر16 مصادرآخر تحديث: 1 sa önce

أحدث الأخبار

SpaceX IPO Filing Highlights Space's Evolution into a Geopolitical and National Security Domain
يتطور
Business·1 g önceملخص الذكاء الاصطناعي

SpaceX IPO Filing Highlights Space's Evolution into a Geopolitical and National Security Domain

SpaceX's IPO filing reveals space's transformation from exploration to a critical domain for national security, communications, and warfare. The company's role in Ukraine via Starlink and its US defense contracts underscore the growing influence of private space firms in military and geopolitical affairs, with India also increasing its focus on spacetech startups for defense.

E
Economic Times
Taiwanese Entrepreneur Aims to Revolutionize Pharmaceuticals with AI
يتطور
Business·2 g önceملخص الذكاء الاصطناعي

Taiwanese Entrepreneur Aims to Revolutionize Pharmaceuticals with AI

Taiwanese entrepreneur Lai Caida shared his entrepreneurial journey at the 18th Straits Forum in Xiamen, aiming to become the "SpaceX of the pharmaceutical industry" with his AI-powered drug delivery platform, Jitaikeji. The company, which started in Hangzhou, has now listed in Hong Kong and Lai invited other Taiwanese youth to pursue opportunities in mainland China.

中国新闻网
Generative AI in Filmmaking: Experimental Projects Shine at Tribeca
يتطور
تقنية·2 g önceملخص الذكاء الاصطناعي

Generative AI in Filmmaking: Experimental Projects Shine at Tribeca

Generative AI's impact on filmmaking is still nascent, with most output being short, inconsistent clips. However, experimental projects at the Tribeca Film Festival, like Google DeepMind's 'Dear Upstairs Neighbors,' demonstrate how human artists can leverage AI as a bespoke tool, suggesting a future of tailored AI models and human-guided creative workflows rather than fully automated content creation.

T
The Verge
Revolution Medicines' Experimental Drug Doubles Survival in Advanced Pancreatic Cancer
يتطور
صحة·2 g önceملخص الذكاء الاصطناعي

Revolution Medicines' Experimental Drug Doubles Survival in Advanced Pancreatic Cancer

Revolution Medicines' experimental drug, daraxonrasib, has shown unprecedented success in treating advanced pancreatic cancer, doubling patient survival rates and significantly reducing the risk of death by 60% compared to standard chemotherapy. The drug, a first-in-class RAS(ON) inhibitor, targets specific RAS gene mutations and demonstrated a remarkable improvement in tumor shrinkage and patient quality of life, with a much lower incidence of severe side effects. The FDA has granted it expanded access and speedy review.

C
Cumhuriyet